A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics,
pharmacodynamics, and preliminary antitumour activity of avelumab (MSB0010718C) in
combination with other cancer immunotherapies in patients with locally advanced or
metastatic solid tumours. The primary purpose is to assess the safety and early signs of
efficacy of various avelumab combinations with other cancer immunotherapies, optimizing
dosing regimens as appropriate, in a limited series of indications.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society